Related Experiment Video
Updated: Jul 6, 2025

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
Published on: April 13, 2015
Coronary slow flow and its correlation with reduced left ventricle global longitudinal strain: a case-control study
Ahmed Shawky Shereef1, Mohamed Gamal Abdelmajeed1, Mohamad Hossam Alshair1
1Department of Cardiology, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Background:
Coronary slow flow (CSF) often links to inflammation and endothelial function disturbance. While conventional ejection fraction measurements fall short in identifying myocardial dysfunction, left ventricular global longitudinal strain (LV GLS) has shown superior efficacy in this regard. Our study aimed to explore subclinical left ventricular systolic dysfunction by assessing LV GLS in patients diagnosed with coronary slow flow (CSF).
Methods:
The study included sixty patients with CSF and sixty control individuals without CSF. Coronary angiography employed the Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) to identify CSF. LV GLS values were evaluated and compared between the two groups.
Results:
Significantly reduced LV GLS was evident in the CSF group compared to the control group (- 16.18 ± 1.25 vs. - 19.34 ± 1.33, p < 0.001). A notable correlation (r = 0.492, p < 0.001) between LV GLS and TFC was observed in the CSF group. Multivariate logistic regression analysis highlighted reduced LV-GLS (OR 2.2, 95% CI 1.57-3.09, p < 0.001) and smoking (OR 11.55, 95% CI 3.24-41.2, p < 0.001) as significant predictors for CSF presence. The receiver operating characteristic curve established that an LV GLS value of ≥ - 17.8% accurately predicted the presence of CSF (AUC: 0.958, 95% CI: 0.924-0.991, p < 0.001) with 90% specificity and 91.7% sensitivity.
Conclusion:
Our study indicates that reduced LV GLS is associated with CSF presence, offering a valuable means to early detect subclinical left ventricular systolic dysfunction in high-risk patients susceptible to heart failure.
Trial Registration:
ZU-IRB#7038/12-7-2021 Registered 12 July 2021, email: IRB_123@medicine.zu.edu.eg.

